Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

By D. Slamon, B. Leyland-Jones, Steven Shak, H. Fuchs, Virginia Paton, A. Bajamonde, Thomas R. Fleming, W. Eiermann, Janet Wolter, M. Pegram and 2 more. New England Journal of Medicine, 2001

5,180 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology

View Paper: https://www.semanticscholar.org/paper/ff1ecfcdae37a53d1797974c8e20fea83b63010c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. H. Horlings
2. M. Karin
3. Gad Getz
4. Peter J. Campbell
5. Véronique Baud
6. D. Hanahan
7. J. Massagué
8. J. Reis-Filho

In Oncology

1. N. Hynes
2. H. Horlings
3. J. Massagué
4. J. Baselga
5. D. Hanahan
6. William Pao
7. R. Weinberg
8. N. Iqbal

Citations in the corpus

• Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. (2004, background): “Unlike the situation for other targeted therapies such as trastuzumab (Genentech, South San Francisco, CA) in breast cancer where a molecular screen to test for HER-2 gene amplification is standard, no such test has been established for gefitinib (or any EGFR tyrosine kinase inhibitor) in NSCLC [14]”
• Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy (2006, background): “HER-2 Breasta Trastuzumab Combination Slamon et al. (2001)28,b, Piccart-Gebhart et al. (2005)29,b”
• Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. (2009, background): “The randomized clinical trial that led to this approval was conducted in combination with standard cytotoxic chemotherapy (Slamon et al., 2001).”
• The transcriptional repressor Snail promotes mammary tumor recurrence. (2005, positive): “The efficacy of this agent in slowing disease progression and prolonging survival, even in advanced stages of disease, has been demonstrated in multiple studies (Baselga et al., 1996; Slamon et al., 2001; Vogel et al., 2002; Wang et al., 2001).”
• Awareness and current knowledge of breast cancer (2017, background): “Human monoclonal antibody Monoclonal antibodies are prepared in the laboratory [256].”
• PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro (2009, background): “Trastuzumab has been shown to have clinical activity in HER2amplified breast cancer [34].”